[Latex allergy. Diagnosis and therapeutic aspects].
In the last two decades of the 20th century, latex allergy has reached epidemic proportions. Epidemiological studies demonstrate that 3-25 % of health personnel is allergic to latex. The main risk groups are health workers, machine operators in latex factories, and children with spina bifida and urogenital anomalies. From the allergenic point of view, latex contains 240 peptides but approximately 50 are able to react to IgE. Latex elongation factor Hevdl is the relevant allergen in patients with spina bifida. Prohevein (hev B6) behaves as a major allergen, since it reacts to IgE in most of the sera of patients with latex allergy. The nature of latex is complex; it is an allergenic mixture that depends on chemical, immunological and epidemiological variables. Latex proteins show strong cross reactivity with several proteins from fruit and vegetable grains such as avocado, potato, banana, tomato, chestnut, and kiwi. In vivo studies have shown that class I chitinase from avocado and chestnut behave as major allergens in allergic patients with latex-fruit syndrome. The clinical manifestations related to the use of latex products depend on the type of exposure, the amount of the allergen, and individual variability. The most useful diagnostic method is the skin prick test. Several perioperative guidelines are recommended in patients sensitized to latex as well as various alternatives to rubber gloves. An increasing number of studies describe the efficacy of etiological treatment (immunotherapy), using different guidelines and routes of administration. These preliminary data encourage the hope that in the near future immunomodulatory therapy will be available to mitigate against the latex allergy epidemic.
Sánchez Palacios
A
A
Unidad de Alergología, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain.
D000328:Adult; D000485:Allergens / Q000009:adverse effects / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D002648:Child; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D003888:Desensitization, Immunologic; D004781:Environmental Exposure; D019665:Euphorbiaceae / Q000009:adverse effects / Q000145:classification / Q000235:genetics / Q000276:immunology; D005260:Female; D005512:Food Hypersensitivity / Q000150:complications; D006282:Health Personnel; D006801:Humans; D016056:Immunodominant Epitopes / Q000276:immunology; D007073:Immunoglobulin E / Q000276:immunology; D007840:Latex / Q000009:adverse effects / Q000737:chemistry; D020315:Latex Hypersensitivity / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D008297:Male; D009754:Nuts / Q000009:adverse effects; D009784:Occupational Diseases / Q000453:epidemiology / Q000209:etiology; D016273:Occupational Exposure; D027421:Persea / Q000009:adverse effects; D010940:Plant Proteins / Q000009:adverse effects / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D012882:Skin Tests; D014546:Urinary Catheterization / Q000009:adverse effects
D000485:Allergens; D016056:Immunodominant Epitopes; D007840:Latex; D010940:Plant Proteins; D007073:Immunoglobulin E